What you should know:
1. Phathom will develop and commercialize Takeda’s potassium competitive acid blocker, vonoprazan, in the U.S., Europe and Canada.
2. Frazier led a $90 million financing round supported by several other investors.
3. Phathom then took out a $50 million loan through Silicon Valley Bank to support developmental efforts.
More articles on gastroenterology:
CHI Franciscan to divest ASC, pay $2.5M to settle anticompetitive lawsuit: 5 things to know
Surgery Partners reports $417M in revenue & more — 10 ASC industry notes
As investors favor ASCs & offices, major skilled nursing operator splits segments
